Antibodies are already widely used in medicine and they have proven effectiveness in the treatment of cancer, HIV, and other infectious diseases. MABLOC’s goal is to utilize these drugs to ameliorate suffering in parts of the world that are often neglected and to rapidly respond to new pandemic threats.
Our company has access to laboratories, research centers, and contacts in several points around the world and has a sophisticated laboratory with access to BSL2 and BSL3 containment facilities in Washington, DC, United States.
MABLOC's team of experts are internationally recognized as authorities in the study and treatment of infectious diseases. Their complementary talents and knowledge help facilitate the development of our antibodies from discovery to clinical use.
The combination of scientific knowledge, experience, and technology makes MABLOC an attractive investment opportunity, with enormous potential for growth.